View Item 

Show simple item record

Prevention of thrombosis and rethrombosis and enhancement of the thrombolytic actions of recombinant tissue‐type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist
dc.contributor.authorLucchessi, Benedict R.en_US
dc.contributor.authorRote, William E.en_US
dc.contributor.authorDriscoll, Edward M.en_US
dc.contributor.authorMu, Dun‐xueen_US
dc.date.accessioned2012-08-09T14:54:41Z
dc.date.available2012-08-09T14:54:41Z
dc.date.issued1994-12en_US
dc.identifier.citationLucchessi, Benedict R.; Rote, William E.; Driscoll, Edward M.; Mu, Dun‐xue (1994). "Prevention of thrombosis and rethrombosis and enhancement of the thrombolytic actions of recombinant tissueâ type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist." British Journal of Pharmacology 113(4). <http://hdl.handle.net/2027.42/92364>en_US
dc.identifier.issn0007-1188en_US
dc.identifier.issn1476-5381en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/92364
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.subject.otherIntegrin Receptoren_US
dc.subject.otherDMP728en_US
dc.subject.otherAnti‐Platelet Agenten_US
dc.subject.otherFibrinogen Receptoren_US
dc.subject.otherThrombolysisen_US
dc.titlePrevention of thrombosis and rethrombosis and enhancement of the thrombolytic actions of recombinant tissue‐type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonisten_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pharmacology, The University of Michigan Medical School, Ann Arbor, MI 48109‐0632, U.S.A.en_US
dc.identifier.pmid7889289en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/92364/1/j.1476-5381.1994.tb17144.x.pdf
dc.identifier.doi10.1111/j.1476-5381.1994.tb17144.xen_US
dc.identifier.sourceBritish Journal of Pharmacologyen_US
dc.identifier.citedreferenceMOUSA, S.A., BOZARTH, J.M., FORSYTHE, M.S., JACKSON, S.A., LEAMY, A., DIEMER, M.J., KAPIL, R.P., KNABB, R.M., MAYO, M.C., PIERCE, S.K., DEGRADO, W.F., THOOLEN, M.J. & REILLY, T.M. ( 1994 ). Antiplatelet, antithrombotic efficacy of DMP728, a novel platelet GPIIb/IIIa receptor antagonist. Circulation, 89, 3 – 12.en_US
dc.identifier.citedreferenceKOUNS, W.C., KIRCHHOFER, D., HADVARY, P., EDENHOFER, A., WELLER, T., PFENNINGER, G., BAUMGARTNER, H.R., JENNINGS, L.K. & STEINER, B. ( 1992 ). Reversible conformational changes in glycoprotein IIb/IIIa by a potent and selective pep‐tidomimetic inhibitor. Blood, 180, 2539 – 2547.en_US
dc.identifier.citedreferenceKROLL, M.H. & SCHAFER, A.I. ( 1989 ). Biochemical mechanisms of platelet activation. Blood, 74, 1181 – 1195.en_US
dc.identifier.citedreferenceMARCUS, A.J. ( 1991 ). Platelets and their disorders. In Disorders of Hemostasis. Ed. Ratnoff, O.D. & Forbes, C.D. pp. 75 – 140. New York: Grune & Stratton.en_US
dc.identifier.citedreferenceMARCUS, A.J. & SAFIER, L.B. ( 1993 ). Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis. FASEB J., 7, 516 – 522.en_US
dc.identifier.citedreferenceMICKELSON, J.K., SIMPSON, P.J., CRONIN, M., HOMEISTER, J.W., LAYWELL, E., KITZEN, J. & LUCCHESI, B.R. ( 1990a ). Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue‐type plasminogen activator‐induced coronary artery thrombolysis in a canine model. Circulation, 81, 617 – 627.en_US
dc.identifier.citedreferenceMICKELSON, J.K., SIMPSON, P.J. & LUCCHESI, B.R. ( 1990b ). Antiplatelet monoclonal F(ab')2 antibody directed against the platelet GP IIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart. J. Mol. Cell. Cardiol., 21, 293 – 405.en_US
dc.identifier.citedreferencePEERLINCK, K., De LEPELEIRE, I., GOLDBERG, M., FARRELL, D., BARRETT, J., HAND, E., PANEBIANCO, D., DECKMYN, H., VERMYLEN, J. & ARNOUT, J. ( 1993 ). MK‐383 (L‐700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist is active in man. Circulation, 88, 1512 – 1517.en_US
dc.identifier.citedreferencePHILLIPS, D.R., FITZGERALD, L.A., CHARO, I.F. & PARISE, L.V. ( 1987 ). The platelet membrane glycoprotein IIb/IIIa complex; structure, function, and relationship to adhesive protein receptors in nucleated cells. Ann. N Y Acad. Sci., 509, 177 – 187.en_US
dc.identifier.citedreferenceROMSON, J.L., HAACK, D.W. & LUCCHESI, B.R. ( 1980 ). Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of anti‐thrombotic agents. Thromb. Res., 17, 841 – 853.en_US
dc.identifier.citedreferenceROTE, W.E., WERNS, S.W., DAVIS, J.H., FEIGEN, L.P., KILGORE, K.S. & LUCCHESI, B.R. ( 1993 ). Platelet GPIIb/IIIa receptor inhibition prevents thrombosis and rethrombosis in the canine carotid artery. J. Cardiovasc. Res., 27, 500 – 507.en_US
dc.identifier.citedreferenceROTE, W.E., MU, D.‐X., BATES, E.R., NEDELMAN, M.A. & LUCCHESI, B.R. ( 1994a ). Prevention of rethrombosis in a chronic canine model. I. Adjunctive therapy with monoclonal antibody 7E3‐F(ab')2 fragment. J. Cardiovasc. Pharmacol., 23, 194 – 202.en_US
dc.identifier.citedreferenceROTE, W.E., DAVIS, J.H., MOUSA, S.A., REILLY T.M. & LUCCHESI, B.R. ( 1994b ). Antithrombotic effects of DMP728, a platelet GPIIb/IIIa receptor antagonist, in a canine model of arterial thrombosis. J. Cardiovasc. Pharmacol., 23, 681 – 689.en_US
dc.identifier.citedreferenceROUSSEAU, G., HEBERT, D., LIBERSAN, D., KHALIL, A., ST‐JEAN, G. & LATOUR, J.‐G. ( 1993 ). Importance of platelets in myocardial injury after reperfusion in the presence of residual coronary stenosis in dogs. Am. Heart J., 125, 1553 – 1563.en_US
dc.identifier.citedreferenceROUX, S.P., TSCHOPP, T.B., KUHN, H., STEINER, B. & HADVARY, P. ( 1993 ). Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb/IIIa receptor antagonist (Ro 43–5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue type plasminogen activator in the dog. J. Pharmacol. Exp. Ther., 264, 501 – 508.en_US
dc.identifier.citedreferenceSALAZAR, A.E. ( 1961 ). Experimental myocardial infarction, induction of coronary thrombosis in the intact closed‐chest dog. Circ. Res., 9, 135 – 136.en_US
dc.identifier.citedreferenceSALDEEN, T.G.P., SALDEEN, P., NICHOLS, W.W., LAWSON, D.L., NICOLINI, F.A. & MEHTA, J.L. ( 1993 ). Increased production of thromboxane A2 by coronary arteries after thrombolysis. Am. Heart J., 125, 277 – 284.en_US
dc.identifier.citedreferenceSCHAFER, A.L., MAAS, A.K., WARE, J.A., JOHNSON, P.C., RITTEN‐HOUSE, S.E. & SALZMAN, E.W. ( 1986 ). Platelet protein phosphorylation, elevation of cytosolic calcium, and inositol phospholipid breakdown in platelet activation induced by plasmin. J. Clin. Invest., 78, 73 – 79.en_US
dc.identifier.citedreferenceSCHWARTZ, L., BOURASSA, M.G., LESPERANCE, J., ALDRIDGE, H.E., KAZIM, R., SALVATORI, V.A., HENDERSON, M., BONAN, R. & DAVID, P.R. ( 1988 ). Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal angioplasty. N. Engl. J. Med., 318, 1714 – 1719.en_US
dc.identifier.citedreferenceTAMI STUDY GROUP ( 1989 ). A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation, 79, 281 – 286.en_US
dc.identifier.citedreferenceTSCHOPP, J.F., DRISCOLL, E.M., MU, D.X., BLACK, S.C., PIERSCH‐BACHER, M.D. & LUCCHESI, B.R. ( 1993 ). Inhibition of coronary artery reocclusion after thrombolysis with an RGD‐containing peptide with no significant effect on bleeding time. Coronary Art. Dis., 4, 809 – 817.en_US
dc.identifier.citedreferenceYAO, S.‐K., OBER, J.C., GONENNE, A., CLUBB, Jr., F.J., KLRISHNAS‐WAMI, A., FERGUSON, J.J., ANDERSON, H.V., GORECKI, M., BUJA, L.M. & WILLERSON, J.T. ( 1993 ). Active oxygen species play a role in mediating platelet aggregation and cyclic flow variations in severely stenosed and endothelium‐injured coronary arteries. Circ. Res., 73, 952 – 967.en_US
dc.identifier.citedreferenceYASUDA, T., GOLD, H.K., YAOITA, H., LEINBACH, R.C., GUERRERO, J.L., JANG, I.‐K., HOLT, R., FALLON, J.T. & COLLEN, D. ( 1990 ). Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue‐type plasminogen activator in a canine preparation. J. Am. Coll. Cardiol., 16, 714 – 722.en_US
dc.identifier.citedreferenceANTIPLATELET TRIALISTS COLLABORATION ( 1988 ). Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br. Med. J., 296, 320 – 321.en_US
dc.identifier.citedreferenceBATES, E.R., MCGILLEM, M.J., MICKELSON, J.K., PITT, B. & MANCINI, G.B.J. ( 1991 ). A monoclonal antibody to the platelet receptor GPIIb/IIIa prevents platelet aggregation and thrombosis in a canine model of coronary artery angioplasty. Circulation, 84, 2463 – 2469.en_US
dc.identifier.citedreferenceBATES, E.R., WALSH, D.G., MU, D.X., ABRAMS, G.D. & LUCCHESI, B.R. ( 1992 ). Sustained inhibition of the vessel wall‐platelet interaction after deep coronary artery injury by temporary inhibition of the platelet glycoprotein IIb/IIIa receptor. Coronary Artery Dis., 3, 67 – 76.en_US
dc.identifier.citedreferenceBAUMGARTNER, H.R. ( 1973 ). The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc. Res., 5, 167 – 179.en_US
dc.identifier.citedreferenceBECKER, R.C. & GORE, J.M. ( 1991 ). Adjuvant antiplatelet strategies in coronary thrombolysis. Circulation, 83, 1115 – 1117.en_US
dc.identifier.citedreferenceCADROY, Y., HOUGHGEN, R.A. & HANSON, S.R. ( 1989 ). RGDV peptide selectively inhibits platelet‐dependent thrombus formation in vivo. Studies using a baboon model. J. Clin. Invest., 84, 939 – 944.en_US
dc.identifier.citedreferenceCAIRNS, J.A. ( 1990 ). Reperfusion adjunctive therapy: heparin. J. Interven. Cardiol., 3, 217 – 223.en_US
dc.identifier.citedreferenceCAIRNS, J.A., HIRSH, J., LEWIS, H.D. Jr., RESNEKOV, L. & THEROUX, P. ( 1992 ). Antithrombotic agents in coronary artery disease. Chest, 102, 456S – 481S.en_US
dc.identifier.citedreferenceCHESEBRO, J.H. & FUSTER, V. ( 1991 ). Dynamic thrombosis and thrombolysis: role of antithrombins. Circulation, 83, 1815 – 1817.en_US
dc.identifier.citedreferenceCOLLER, B.S. ( 1990 ). Platelets and thrombolytic therapy. N. Engl. J. Med., 322, 333 – 342.en_US
dc.identifier.citedreferenceCOLLER, B.S. ( 1992 ). Antiplatelet agents in the prevention and therapy of thrombosis. Annu. Rev. Med., 43, 171 – 180.en_US
dc.identifier.citedreferenceDENNIS, M.S., HENZEL, W.J., PITTI, R.M., LIPARI, M.T., NAPIER, M.A., DEISHER, T.A., BUNTING, S. & LAZARUS, R.A. ( 1990 ). Platelet GPIIb/IIIa from snake venoms: evidence for a family of platelet aggregation inhibitors. Proc. Natl. Acad. Sci. U.S.A., 87, 2471 – 2475.en_US
dc.identifier.citedreferenceFALK, E. ( 1985 ). Unstable angina with fatal outcome dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation, 71, 699 – 708.en_US
dc.identifier.citedreferenceFITZGERALD, D.J., DORAN, J., JACKSON, E. & FITZGERALD, G.A. ( 1986 ). Coronary vascular occlusion mediated via thromboxane A2‐prostaglandin endoperoxide receptor activation in vivo. J. Clin. Invest., 77, 496 – 502.en_US
dc.identifier.citedreferenceFITZGERALD, D.J., CATELLA, R., ROY, L. & FITZGERALD, G.A. ( 1988a ). Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation, 77, 142 – 150.en_US
dc.identifier.citedreferenceFITZGERALD, D.J., WRIGHT, R. & FITZGERALD, C.A. ( 1988b ). Thrombin‐mediated platelet activation during thrombolysis (abstract). Circulation, 78 ( Suppl. 2 ), 120.en_US
dc.identifier.citedreferenceGATTER, K.C., CORDELL, J.L., TURLEY, H., HERYET, A., KIEFFER, N., ANSTEE, D.J. & MASON, D.Y. ( 1988 ). The immunohistological detection of platelets, megakaryocytes and thrombi in routinely processed specimens. Histopathology, 13, 257 – 267.en_US
dc.identifier.citedreferenceGINSBERG, M.H., LOFTUS, J.C. & PLOW, E.F. ( 1988a ). Cytoadhesions, integrins and platelets. Thromb. Haemost., 59, 1 – 6.en_US
dc.identifier.citedreferenceGINSBERG, M.H., LOFTUS, J.C. & PLOW, E.F. ( 1988b ). Platelets and the adhesion receptor superfamily. Prog. Clin. Biol. Res., 283, 171 – 195.en_US
dc.identifier.citedreferenceGISSI TRIAL (GRUPPO ITALIANO PER LO STUDIO DELLA STREPTOKINASE NELLINFARTO MIOCARDICO) ( 1986 ). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet, 1, 397 – 402.en_US
dc.identifier.citedreferenceGOLD, H.K., GIMPLE, L.W., YASUDA, T., LEINBACH, R.C., WERNER, W., HOLT, R., JORDAN, R., BERGER, H., COLLEN, D. & COLLER, B.S. ( 1990 ). Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J. Clin. Invest., 86, 651 – 659.en_US
dc.identifier.citedreferenceGOULD, R.J., POLOKOFF, M.A., FRIEDMAN, P.A., HUANG, T.‐F., HOLT, J.C, COOK, J.J. & NIEWIAROWSKI, S. ( 1990 ). Disintegrins: a family of integrin inhibitory proteins from viper venoms. Proc. Soc. Exp. Biol. Med., 195, 168 – 171.en_US
dc.identifier.citedreferenceGRINES, C.L. ( 1992 ). Thrombolytic, antiplatelet, and antithrombotic agents. Am. J. Cardiol., 70, 18‐I – 26‐I.en_US
dc.identifier.citedreferenceGROVES, H.M., KINLOUGH‐RATHBONE, R.L. & MUSTARD, J.F. ( 1986 ). Development of nonthrombogenicity of injured rabbit aortas despite inhibition of platelet adherence. Atherosclerosis, 6, 189 – 195.en_US
dc.identifier.citedreferenceGUCCIONE, M.A., KINLOUGH‐RATHBONE, R.L., PACKHAM, M.A., HARFENIST, E.J., RAND, M.L., GREENBERG, J.P., PERRY, D.W. & MUSTARD, J.F. ( 1985 ). Effect of plasmin on rabbit platelets. Thromb. Haemost., 53, 8 – 14.en_US
dc.identifier.citedreferenceGUSTO INVESTIGATORS ( 1993 ). An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med., 329, 673 – 682.en_US
dc.identifier.citedreferenceHARKER, L.A. ( 1986 ). Clinical trials evaluating platelet‐modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. Circulation, 73, 206 – 223.en_US
dc.identifier.citedreferenceHARKER, L.A. ( 1987 ). Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am. J. Cardiol., 60, 20B – 28B.en_US
dc.identifier.citedreferenceHARRISON, M.J.G. ( 1990 ). Role of platelets and antiplatelet agents in cerebrovascular disease: clues from trials. Circulation, 81 Suppl. I ), 120 – 121.en_US
dc.identifier.citedreferenceISIS‐2 (SECOND INTERNATIONAL STUDY OF INFARCT SURVIVAL COLLABORATIVE GROUP) ( 1988 ). Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected myocardial infarction: ISIS‐2. J. Am. Coll. Cardiol., 12 ( Suppl. A ), 3A – 13A.en_US
dc.identifier.citedreferenceKIEFFER, N. & PHILLIPS, D.R. ( 1990 ). Platelet membrane glycoproteins: functions in cellular interactions. Annu. Rev. Cell. Biol., 6, 329 – 357.en_US
dc.identifier.citedreferenceKIEFFER, N., GUICHARD, J. & BRETON‐GORIUS, J. ( 1992 ). Dynamic redistribution of major platelet surface receptors after contact‐induced platelet activation and spreading. Immunoelectron microscopy study. Am. J. Pathol., 140, 57 – 73.en_US
dc.identifier.citedreferenceKLEIMAN, N.S., OHMAN, E.M., CALIFF, R.M., GEORGE, B.S., KER‐EIAKES, D., AGUIRRE, F.V., WEISMAN, H., SCHAIBLE, T. & TOPOL, E.J. ( 1993 ). Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J. Am Coll. Cardiol., 22, 381 – 389.en_US
dc.identifier.citedreferenceKOHMURA, C., GOLD, H.K., YASUDA, T., HOLT, R., NEDELMAN, M.A., GUERRERO, J.L., WEISMAN, H.F. & COLLEN, D. ( 1993 ). A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue‐type plasminogen activator in baboons. Arteroscler. Thromb., 13, 1837 – 1842.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1476-5381.1994.tb17144.x.pdf
Size:
2.283MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.